Temozolomide is the only first-line drug in the treatment of recurrent glioma, and the levels of DNA repair gene O6-methylguanine DNA methyltransferase (MGMT) indicated sensitivity to the drug [6]. The gene discussed is MGMT; the disease is glioma.